Affiliation:
1. Clinical Mass Spectrometry Center, Guangzhou KingMed Center for Clinical Laboratory Co.,Ltd
2. Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union
Abstract
Abstract
Urinary and plasma 18-hydroxycortisol (18-OHF) have been investigated for primary aldosteronism (PA) subtyping. However, there is no research exploring the impact of sample types on the diagnostic performance of 18-OHF in PA subtyping. In this study, 18-OHF levels in both urine and plasma were determined in patients with idiopathic adrenal hyperplasia (IHA), aldosterone-producing adenoma (APA), and essential hypertension (EH) by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Urinary18-OHF was determined using an established LC-MS/MS method, whereas plasma18-OHF was measured by a modified LC-MS/MS method. Differences in urinary and plasma 18-OHF levels between APA, IHA, and EH patients were investigated by Kruskal-Wallis test for non-parametric analysis. The LC-MS/MS method yielded a lower limit of quantitation (LLOQ) of 18-OHF in urine of 4.28 nmol/L and 0.190 nmol/L in plasma. The intra- and inter-precision for urine and plasma methods were < 6%, with accuracies between 95.9% and 110.3%. Urinary and plasma 18-OHF in 12 IHA, 18 APA, and 91 EH patients were quantified and analyzed. Non-parametric analysis by Kruskal-Wallis test revealed that urinary 18-OHF levels in IHA and APA patients were significantly different (P < 0.05) while plasma 18-OHF levels were not (P > 0.05), indicating that urinary 18-hydroxycortisol outperformed plasma 18-hydroxycortisol for primary aldosteronism subtyping.
Publisher
Research Square Platform LLC